[Analysis of actual costs in long-term therapy of reflux disease. Use of pantoprazole counts].
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D016568:Drugs, Generic / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D005194:Family Practice; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000191:economics*; D005858:Germany; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D013607:Tablets; D013997:Time Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D016568:Drugs, Generic; D054328:Proton Pump Inhibitors; D013607:Tablets; D000077402:Pantoprazole; D009853:Omeprazole